The Global Health Body Issues Concern Over Acute Shortage of Obesity Jabs
Fewer than one in 10 patients that would benefit from weight-loss injections such as Wegovy can access them, warns the World Health Organization as it releases its first advice on the medications.
Considering in excess of 1,000,000,000 people worldwide currently obese, it is urging broader and more equitable availability to these injectable treatments.
Based on projections, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.
"The new guidelines acknowledges that obesity is a lifelong illness that can be managed with thorough and lifelong care," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are significant barriers to broad access to the treatments that can aid individuals in losing substantial body mass, says the body.
Skinny Jab Scarcity
Despite the current most optimistic scenario, the production of GLP-1 therapies could only cover around 100 million people – fewer than 10% of the global need, according to the health organization.
The guideline encourages nations and manufacturers to increase availability, via measures including patent sharing.
The intellectual property rights on a key compound – the primary ingredient of a leading brand – is set to lapse in a number of countries in 2026.
How Obesity Drugs Work
These medications mimick a biological compound to slow digestion, reduce hunger and enhance satiety so users consume fewer calories.
People typically see weight reduction within a few weeks of commencing the once-weekly jabs.
Evidence suggests users may see weight return a year later of stopping the treatment, when their normal appetite return.
Being carrying excess weight increases your risk for developing medical conditions, including type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight concerns individuals in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, as per the WHO.